SCHEDULE 13G/A 0001104659-24-106486 0001577164 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 06/30/2025 0001617867 Autonomix Medical, Inc. 05330T205 21 Waterway Avenue, Suite 300 The Woodlands TX 77380 Rule 13d-1(d) BioStar Ventures III, L.P. b DE 175216.00 0.00 175216.00 0.00 175216.00 4.3 PN BioStar Ventures III, L.L.C. b DE 0.00 175216.00 0.00 175216.00 175216.00 4.3 OO Autonomix Medical, Inc. 21 Waterway Avenue, Suite 300, The Woodlands, TX, 77380. The names of the persons filing this report (collectively, the "Reporting Persons") are: BioStar Ventures III, L.P. ("BioStar III") BioStar Ventures III, L.L.C. ("BioStar III GP") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. 206 Bridge Street, Charlevoix, MI 49720 BioStar III Delaware BioStar III GP Delaware Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. BioStar III directly holds (i) 120,816 shares of common stock and (ii) warrants (the "Warrants") exercisable for up to 54,400 shares of common stock. BioStar III GP is the general partner of BioStar III and shares voting and dispositive power over the securities held by BioStar III. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in row 11 is based upon 4,022,625 shares of common stock outstanding as of June 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2025, adjusted in accordance with rules of the SEC to include shares issuable upon exercise of the Warrants. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. N Y Y Y Y Y Y Exhibit 99.1 Joint Filing Agreement BioStar Ventures III, L.P. /s/ Louis Cannon, MD 08/14/2025 BioStar Ventures III, L.L.C. /s/ Louis Cannon, MD 08/14/2025